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SHORT SUMMARY
A systematic literature review of the incidence of primary glomerulonephritis is presented. 40 papers published between 1980 and 2010 were critically appraised and included in the review.
Overall, incidence was found to be between 0.2 and 2.5 /100 000/year in adults with lower incidence rates in children, for most types of glomerulonephritis.
INTRODUCTION
Although much is known about clinical characteristics and natural history of the primary glomerulopathies, very little information on the epidemiology of these diseases is available from reviews. Insight into the baseline incidence of glomerulonephritis throughout the world can provide important information on trends of disease occurrence by sex, age and geographical location. New vaccines are being introduced and concerns have been raised about the potential associated risk of autoimmune diseases (46, 47) . It is therefore of interest to know what the baseline incidence rates across the world are so that concerns about possibly associated increased incidence rates of autoimmune diseases, such as glomerulonephritis, can be evaluated.
To our knowledge no other systematic review of incidence of the most common of the primary glomerulopathies has been conducted in the last three decades. In this paper we perform a systematic review, critically appraising studies of incidence of primary glomerulonephritis throughout the world.
Method
Searches of the Medline, EMBASE and Science Direct databases (1980 ( -June 2007 were carried out using the search terms 'glomerulonephritis,' 'IgA nephropathy', 'membranous nephropathy', 'membranoproliferative glomerulonephritis', 'mesangial proliferative glomerulonephritis', 'minimal change disease', 'focal segmental glomerulosclerosis', 'postinfectious glomerulonephritis', 'idiopathic crescentic proliferative glomerulonephritis', 'ANCAassociated necrotising crescentic glomerulonephritis', 'anti glomerular basement membrane disease', 'kidney disease', 'incidence', 'incid*' and 'epidemiology.' In Medline, the individual disease names were searched for as well as the term 'glomerulonephritis' because this MeSH term does not include all types of glomerulonephritis as daughter terms in its hierarchical structure.
The inclusion criteria were that the studies reported original work, that the study reported incidence of specific forms of glomerulonephritis with reference to a denominator population, that the estimates of population size and persontime contributed were accurate and that efforts had been made to ascertain all incident cases. When assessing the likelihood of missing incident cases, papers were evaluated as follows: 1) for case finding studies, did the authors ensure that all of the subjects contributing to incidence denominator data would have been eligible to have the disease diagnosed and did the authors check all relevant medical records?
2) For all studies, were cases checked to ensure that they were incident and not prevalent? 3) For all studies, did the authors ensure that the cause of glomerulonephritis was autoimmune and not secondary to another disease? Where possible we only included incidence rates for cases of glomerulonephritis caused by autoimmunity, determination of which relied on information given in the paper.
The titles and abstracts of all of the studies produced by the searches were reviewed and those papers accepted for inclusion in the study were appraised. Studies published in English, French, German, Spanish or Dutch were included. Review papers identified were searched for secondary references reporting on original research; secondary references found from any of the other papers reviewed were also included.
A standard data abstraction form was used to record all details of the papers reviewed; a copy of this is given in the Appendix, figure 1A. Each study was scored for accuracy of the incidence rates it presented and was classified as being at low, medium or high risk for under or over estimation of reported incidence rates by considering the reliability of numerator and denominator data. For instance, inclusion of prevalent cases or those thought not to be caused by autoimmunity will have led to overestimated rates as will underestimated denominator data. Conversely, missing cases or an overestimated denominator (e.g. a catchment area from which not all inhabitants had access to hospital services) would be considered to have resulted in underestimated incidence rates.
Explanations provided by the papers' authors as to why incidence rates were as expected or whether they were considered to be an over or underestimate of the true incidence rate were taken into account in this process. If the extent of likely error was considered to be very great, the study was excluded. To minimise subjectivity, this assessment was agreed between two of the authors and random checks were performed to ensure consistency. Rates are presented as the number of cases/100 000/year and where sufficient data were given in the paper, rates were checked for accuracy. Guidelines were followed in the reporting of this study to ensure that key information was presented (1).
Results
The results of the database searches with the number of included and excluded papers are given in figure 1 ; the excluded references are available on request from the authors.
Most of the papers rejected at abstract review stage did not report on primary and autoimmune glomerulonephritis and had been found from the search using 'kidney disease' as the search term. Of the remaining papers, reasons for rejecting included those reporting on an ill subgroup of the population (e.g. those with systemic lupus erythematosus), those that reported on prevalence and not incidence, review papers and those that gave incidence rates as a percentage of people who had a renal biopsy. For some types of glomerulonephritis, the terms used by authors varied, some using the term to describe clinical presentation or syndrome for example crescentic proliferative (2) or crescentic glomerulonephritis (3 5), nephrosis (2,6), rapidly progressive glomerulonephritis (7,8), acute glomerulonephritis (9) and acute nephritis (10) whereas others used non specific terms such as vasculitis (1115) and total glomerulonephritis (9).
These incidence rates have been excluded from the review because it was impossible to determine the extent to which these papers reported on primary and autoimmune glomerulonephritis.
Descriptions of the studies are given in Mesangial proliferative glomerulonephritis : four studies included were prospective and three were retrospective; all gave incidence rates between 0.2 /100 000/year and 1.1/100 000/year (3,5,6,26,27,44). In order to differentiate mesangial proliferative glomerulonephritis from IgA nephropathy, immunofluorescence should be used. All seven studies used immunofluorescence in their studies but four reported that this was not performed on all biopsies (26,27,30,44) giving a potential overestimation of the incidence rate. The only study to make the distinction between IgA nephropathy and mesangial proliferative glomerulonephritis without IgA deposits was that by Schena et al (5), who found an incidence rate of 0.16/100,000/year therefore it is likely the 'true' incidence rate of mesangial proliferative glomerulonephritis is at the lower end of the range given.
Minimalchange disease: in children, minimal change disease has been found to cause over 75% of cases of nephrotic syndrome (46) . Seven studies reported on incidence of nephrotic syndrome, which would produce a slight overestimation of incidence of minimal change disease In the remaining studies, retrospective and prospective studies reported similar rates between 0.2/100 000/year and 0.8/100 000/year in adults (3,5,9,11,15,18,21,26,27,29,30,35,38,39,44); no trend of changes over time was found. Taking into account the accuracy of these rates, our best estimate of incidence of minimal change disease in adults is 0.6/100 000/year.
Focal segmental glomerulosclerosis: most rates, whether from prospective or retrospective studies, were between 0.2 /100 000/year and 1.1 /100 000/year; the Australian study reported the highest rates of 2.5/100 000/year in males and 1.8/100 000/year in females. The latter may be due to the fact that in Australia, people are referred for biopsy more often than in other countries included in this review (11). In the three studies that investigated differences in rates between males and females, incidence appeared to be higher in males (9,11,13). However no indication was given of the statistical significance of these differences and given the fact that the numbers of cases were low, they may have arisen by chance.
Other types of glomerulonephritis: Incidence rates were presented for other types of glomerulonephritis, however these were limited to just one or two studies per disease type. Details are given in the forest plots:
generally these rates were low at less than 1.0 /100 000/year. However
Becquet et al. (16) in their study of postinfectious glomerulonephritis in French Polynesia, reported an incidence rate of 18/100 000/year; this is likely to be an underestimate of the true rate. This country had a higher rate of bacterial infections due to the climatic conditions, greater numbers of people sharing residences, low socioeconomic level and a lower use of medical care due to cultural beliefs; these factors are all thought to contribute to this higher incidence rate.
Accuracy of incidence rates
There are a number of components to assess when considering the incidence rates presented. Indication of likely accuracy of rates has been given in table 1. Of key importance is whether the cases included in the numerator were new cases: six studies reported in their methods section that only new cases were included (2,4,6,9,22,24,36,37). As glomerulonephritis is diagnosed by biopsy, the more liberal the biopsy policy, the greater the possibility of detecting all cases of the disease.
Some studies gave their biopsy rate per head of population: these are given in table 1 and vary between 1.08 and 24.7 /100 000/year (6,11,14,18,19,21,2630,35,38,39,44).
Discussion
This literature review found incidence rates for different types of primary autoimmune glomerulonephritis to be between 0.2/100 000/year and 2.5/100 000/year in adults. Most studies were from the US and France therefore it is difficult to draw conclusions regarding variability of rates with geographical location or ethnicity. Given that glomerulonephritis can exist subclinically, and given differences in access to renal biopsy between different healthcare systems, it is likely that geographical variations in incidence rates found can be explained by differences in diagnosis rather than by genuine difference in disease frequency.
It is useful to note the type of studies undertaken to determine incidence of glomerulonephritis: in reviews of incidence of other autoimmune diseases (47, 48) , prospective studies are thought to have given more accurate rates than retrospective studies. However, in the studies presented here the rates reported were consistent irrespective of the study type.
Most studies used biopsy to diagnose the disease for the majority of cases Mazzuchi et al (15) reported rates using a national registry and found an increase in incidence with time they reported to be due to a greater awareness of the disease and earlier diagnosis.
Cases of IgA nephropathy can exist subclinically and therefore will only be diagnosed through routine urinary tests or if a patient presents with severe symptoms (27): Simon et al. (6) reported that 60% of cases of idiopathic IgA nephropathy were discovered by chance through routine testing as part of a medical examination in employment. Screening populations for conditions that can exist subclinically will produce higher and more accurate incidence rates especially when done routinely so that prevalent cases are not included in the incidence rate. In this review one study (42) used a regular screening program to find cases and the rate produced was greater by nearly an order of magnitude than other comparable incidence rates. Sehic et al. (33) reported that many cases of
IgA are never diagnosed and that limited access to medical care for those of lower socioeconomic status may explain some failure to diagnose in this study.
There is the possibility of cases of secondary glomerulonephritis being included as primary cases particularly in retrospective studies; this would lead to an overestimation of incidence rates. There are links, for example between membranoproliferative glomerulonephritis and hepatitis B or hepatitis C. Variations between countries in terms of rates of infections will contribute to differences in incidence rates.
One of the key factors in explaining differences in incidence rates of glomerulonephritis is the difference in referral and biopsy policies between different countries and even between regions of countries (14,21,28,29).
Briganti et al. reported an increase in incidence at 45 years and over which was thought to be due to a more proactive attitude towards conducting diagnostic procedures in the elderly. It is likely that incidence in older people is underestimated as not all cases were referred to specialists or underwent biopsies (9).
Conclusion
Reported incidence rates of glomerulonephritis in adults varied between 0.2 and 2.5 /100 000 /year depending on the type of glomerulonephritis.
Incidence in children was generally lower with most rates around 0.1 /100 000 /year; two exceptions to this were that incidence of minimal change disease in children was around 2.0 /100 000/year and a screening study that reported a rate of IgA nephropathy of 4.5 /100 000 /year in children in Japan.
The reported incidence rates are likely to underestimate true rates of IgA nephropathy as this disease can exist subclinically and may never be detected however other types of glomerulonephritis may be overestimated due to relapses and prevalent cases being counted as incident. There is variation in biopsy policy between countries, which affects the incidence rates found. Incidence in older people appears to have increased over time: this is considered to be due to greater inclusion of this age group in referrals for biopsy rather than due to a genuine increase in disease occurrence.
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